Truist Financial Issues Positive Forecast for CVS Health (NYSE:CVS) Stock Price

CVS Health (NYSE:CVS) had its price target lifted by stock analysts at Truist Financial from $98.00 to $102.00 in a note issued to investors on Thursday,MarketScreener reports. The firm currently has a “buy” rating on the pharmacy operator’s stock. Truist Financial’s target price points to a potential upside of 16.31% from the company’s current price.

A number of other analysts have also weighed in on the stock. The Goldman Sachs Group upped their price target on shares of CVS Health from $95.00 to $97.00 and gave the stock a “buy” rating in a research note on Thursday, February 12th. Wolfe Research decreased their target price on CVS Health from $100.00 to $97.00 and set an “outperform” rating for the company in a research note on Monday, March 2nd. Leerink Partners restated an “outperform” rating and set a $98.00 price objective on shares of CVS Health in a research report on Thursday, March 5th. Barclays restated an “overweight” rating and set a $101.00 target price on shares of CVS Health in a report on Thursday. Finally, Argus decreased their target price on CVS Health from $91.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, January 28th. Twenty-two investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, CVS Health currently has an average rating of “Moderate Buy” and an average price target of $95.20.

CVS Health Stock Performance

Shares of NYSE:CVS traded up $0.84 during trading on Thursday, hitting $87.70. 563,188 shares of the company traded hands, compared to its average volume of 8,423,662. The stock has a market capitalization of $112.39 billion, a price-to-earnings ratio of 63.60, a PEG ratio of 0.84 and a beta of 0.60. CVS Health has a one year low of $58.35 and a one year high of $88.63. The company has a quick ratio of 0.63, a current ratio of 0.84 and a debt-to-equity ratio of 0.80. The business’s fifty day moving average is $76.60 and its 200-day moving average is $78.00.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The business had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. During the same quarter in the prior year, the firm earned $2.25 earnings per share. The company’s quarterly revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, equities analysts predict that CVS Health will post 7.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CVS Health

Institutional investors have recently modified their holdings of the stock. Sei Investments Co. raised its holdings in shares of CVS Health by 17.4% during the second quarter. Sei Investments Co. now owns 905,715 shares of the pharmacy operator’s stock worth $62,474,000 after acquiring an additional 134,535 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in CVS Health by 1.2% in the second quarter. The Manufacturers Life Insurance Company now owns 1,121,377 shares of the pharmacy operator’s stock valued at $77,353,000 after purchasing an additional 13,329 shares in the last quarter. Treasurer of the State of North Carolina increased its position in CVS Health by 1.3% in the 2nd quarter. Treasurer of the State of North Carolina now owns 585,073 shares of the pharmacy operator’s stock worth $40,358,000 after purchasing an additional 7,588 shares during the last quarter. HUB Investment Partners LLC raised its stake in shares of CVS Health by 25.0% during the 2nd quarter. HUB Investment Partners LLC now owns 15,063 shares of the pharmacy operator’s stock worth $1,039,000 after purchasing an additional 3,011 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in shares of CVS Health by 8.0% during the 2nd quarter. Alliancebernstein L.P. now owns 1,609,404 shares of the pharmacy operator’s stock valued at $111,017,000 after buying an additional 119,439 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Q1 beat and guidance raise — CVS posted adjusted EPS of $2.57 and revenue of $100.4B, topping estimates, and raised FY?2026 adjusted EPS guidance to $7.30–$7.50, signaling better-than-expected operating performance and giving investors more confidence in 2026 earnings. CVS Health raises 2026 forecast after improving medical cost controls
• Positive Sentiment: Insurance turnaround driving profits — CVS reported roughly $2.9B in Q1 net income as Aetna’s medical benefit ratio improved (84.6% vs. 87.3% prior year), easing a prior drag and materially contributing to the beat. That improvement is central to the stock’s strength. CVS Health reports $2.9B in Q1 profit as Aetna strengthens
• Positive Sentiment: Management confidence on margins — Executives said Aetna is on a path to meet Medicare Advantage margin goals by 2028 after five consecutive quarters of improvement, reducing execution risk for the insurance segment. CVS execs say company on track to meet MA margin goals by 2028
• Positive Sentiment: Pharmacy cost initiatives — CVS Caremark will expand biosimilar formulary adoption (effective July 1), which should lower drug costs and support pharmacy margin improvement over time. CVS Caremark Expands Biosimilar Adoption
• Negative Sentiment: Analyst view still cautious — HSBC raised its price target from $83 to $85 but kept a “hold” rating; the PT sits below the stock’s current level, indicating some analysts see limited near-term upside. That dampens how bullish some investors will be despite the beat. HSBC Raises CVS Health Price Target to $85.00

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.